Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position
about
Rational design of potent, small, synthetic allosteric inhibitors of thrombinFragment deconstruction of small, potent factor Xa inhibitors: exploring the superadditivity energetics of fragment linking in protein-ligand complexesAdvances in the development of thrombin inhibitorsA network-based multi-target computational estimation scheme for anticoagulant activities of compoundsSmall, noncovalent serine protease inhibitors.Contribution of explicit solvent effects to the binding affinity of small-molecule inhibitors in blood coagulation factor serine proteases.Synthesis and biochemical evaluation of triazole/tetrazole-containing sulfonamides against thrombin and related serine proteases.Quantum and molecular dynamics study for binding of macrocyclic inhibitors to human alpha-thrombin.Designing allosteric regulators of thrombin. Monosulfated benzofuran dimers selectively interact with Arg173 of exosite 2 to induce inhibition.Free Fatty Acids Modulate Thrombin Mediated Fibrin Generation Resulting in Less Stable Clots.(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.Oral, direct thrombin and factor Xa inhibitors: the replacement for warfarin, leeches, and pig intestines?The application of bioisosteres in drug design for novel drug discovery: focusing on acid protease inhibitors.Cl-pi interactions in protein-ligand complexes.4-Fluoroprolines: Conformational Analysis and Effects on the Stability and Folding of Peptides and Proteins.Site-Specific Fragment Identification Guided by Single-Step Free Energy Perturbation CalculationsA fluorine scan of the phenylamidinium needle of tricyclic thrombin inhibitors: effects of fluorine substitution on pKa and binding affinity and evidence for intermolecular C-F...CN interactions.
P2860
Q24623182-76B01362-F48E-49A3-97B0-CD3E68D8D3A4Q27676351-809429D7-E1AE-4FC4-B26F-F4F8A8D78824Q28182480-D54B1DFC-32BB-4D79-8510-42539C1C0F7AQ28477458-DFA02F26-E68C-43BC-ABE2-E7C0C626DFDFQ33585640-9EEBA09D-6D16-46AD-ACD2-36165922A798Q33877415-8B173D04-9936-463B-829A-28FADEDF2796Q33977957-BB31A587-0A95-453A-BB6B-78E1373FCD1FQ35812336-108F4788-E88D-4587-BBE7-EDB927328119Q36157083-1A13A6CA-AEB5-4CA3-BFC3-0E22B39762ABQ36220016-C8F8B511-5733-472E-B74C-49FFE4854E6BQ36294009-1309B46B-C918-4DD2-893F-6C86B8D45ADCQ37871535-FD7B9AFE-A74B-4B31-833B-44CC63D6FB1BQ38032909-5CEB3E85-3462-44C5-9372-77018C426DA8Q39639555-4BF9FEFA-CB11-4F81-A7D4-3894E0FF3DCBQ40959208-8A34B73B-4EA3-491A-9D47-39EA4EA41448Q41451646-93B228DB-404D-4B92-BAD0-8405D0775500Q44857393-DCAE1DB6-1BE6-4811-8DF8-B3D1F6980598
P2860
Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position
description
1998 nî lūn-bûn
@nan
1998 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Design and synthesis of a seri ...... asic groups in the P1 position
@ast
Design and synthesis of a seri ...... asic groups in the P1 position
@en
Design and synthesis of a seri ...... asic groups in the P1 position
@nl
type
label
Design and synthesis of a seri ...... asic groups in the P1 position
@ast
Design and synthesis of a seri ...... asic groups in the P1 position
@en
Design and synthesis of a seri ...... asic groups in the P1 position
@nl
prefLabel
Design and synthesis of a seri ...... asic groups in the P1 position
@ast
Design and synthesis of a seri ...... asic groups in the P1 position
@en
Design and synthesis of a seri ...... asic groups in the P1 position
@nl
P2093
P356
P1476
Design and synthesis of a seri ...... asic groups in the P1 position
@en
P2093
A M Naylor-Olsen
C M Cooper
E P Baskin
J A Krueger
P304
P356
10.1021/JM9801713
P407
P577
1998-08-13T00:00:00Z